A randomized, double-blind, placebo-controlled study of flexible doses of levomilnacipran ER (40–120 mg/day) in patients with major depressive disorder

OBJECTIVE: Levomilnacipran ER is a potent and selective serotonin and norepinephrine reuptake inhibitor (SNRI) approved for the treatment of major depressive disorder (MDD). Efficacy and safety have been evaluated in five Phase II/III studies, four of which met the pre-specified primary efficacy out...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:J Drug Assess
Hauptverfasser: Gommoll, Carl P., Greenberg, William M., Chen, Changzheng
Format: Artigo
Sprache:Inglês
Veröffentlicht: Taylor & Francis 2014
Schlagworte:
Original Articles
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4937636/
https://ncbi.nlm.nih.gov/pubmed/27536449
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3109/21556660.2014.884505
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge